Tafnat-EM (Emtricitabine + Tenofovir) Tablets

Description

Description

This page contains brief details about the drug emtricitabine,tenofovir alafenamide, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Emtricitabine + Tenofovir alafenamide is a combination of anti-retroviral drug. Emtricitabine belongs to the class of medication called nucleoside reverse transcriptase inhibitor (NRTI), and Tenofovir alafenamide belongs to the class called nucleotide reverse transcriptase inhibitor (NtRTI). FDA approved it initially in September 2015 for its medical use.

Mechanism of Action of Emtricitabine + Tenofovir

Emtricitabine and Tenofovir alafenamide are nucleoside/nucleotide analog reverse transcriptase inhibitors, exhibiting their antiviral effect by competing with natural substrates and incorporating them into viral DNA, resulting in the termination of the DNA chain.

Uses of Emtricitabine + Tenofovir

Emtricitabine+Tenofovir alafenamide is used in combination with other medicines to treat human immunodeficiency virus (HIV-1) infection in adults and adolescents 12 years of age and who weigh at least 35kg. They work by slowing the spread of HIV in the body.

Emtricitabine + Tenofovir Dosage available

It is an orally available prescription drug. Your doctor will decide the dose and duration of Emtricitabine+Tenofovir alafenamide based on the disease condition and other factors such as body weight and age. Always take this medicine as prescribed by your doctor. Take the tablet at the same time, with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with a glass of water. If you have difficulty swallowing the tablet, you can split it in half after consulting with your doctor.